mk-0533
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT00543959)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
PPARG modulator
Ph2 study terminated, compound development discontinued. Selective PPAR gamma modulator (SPPAR?M)
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O- Mol. weight
- 527.5 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL490029 ↗
Also known as
- mk0533
- mk0533
- mk-0533
- mk-0533
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00543959 | Phase 2 | Jun 1, 2006 | Merck |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1